{"entity": "journal", "iuid": "6eff4a2e04a64250a9e76c33f35b2058", "timestamp": "2026-08-20T20:45:17.757Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/Thyroid%20Res.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/Thyroid%20Res"}}, "title": "Thyroid Res", "issn": "1756-6614", "issn-l": null, "publications_count": 1, "publications": [{"entity": "publication", "iuid": "ccdc037f99d04f6c8e00541d24b23cf5", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/ccdc037f99d04f6c8e00541d24b23cf5.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/ccdc037f99d04f6c8e00541d24b23cf5"}}, "title": "CD44v6 expression in non-anaplastic thyroid carcinoma: characterization of candidates for targeted therapy.", "authors": [{"family": "Stenman", "given": "Adam", "initials": "A"}, {"family": "Nilsson", "given": "Joachim N", "initials": "JN"}, {"family": "Condello", "given": "Vincenzo", "initials": "V"}, {"family": "L Mortensen", "given": "Anja C", "initials": "AC"}, {"family": "Nestor", "given": "Marika", "initials": "M"}, {"family": "Zedenius", "given": "Jan", "initials": "J"}, {"family": "Juhlin", "given": "C Christofer", "initials": "CC", "orcid": "0000-0002-5945-9081", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c155b3a3146b41909170a016a7f5b07a.json"}}], "type": "journal article", "published": "2025-10-03", "journal": {"title": "Thyroid Res", "issn": "1756-6614", "volume": "18", "issue": "1", "pages": "47", "issn-l": null}, "abstract": "CD44v6 is a membranous antigen upregulated in solid tumors and a promising molecular radiotherapy target, especially in anaplastic thyroid carcinoma (ATC). A Phase 1 trial recently launched to evaluate the lutetium-labeled anti-CD44v6 antibody [1\u2077\u2077Lu]Lu-DOTA-AKIR001 in CD44v6-positive solid tumors. Given limited data in non-ATC, we assessed CD44v6 immunoreactivity in tumors that may progress to a radioiodine-refractory state.\n\nAn exploratory cohort of 33 tumors (30 papillary thyroid carcinomas [PTCs], 3 poorly differentiated thyroid carcinomas [PDTCs]) was screened using the VFF-7 antibody, supported by detailed iodine concentration, genetic, and RNA sequencing data. A validation cohort of 40 oncocytic thyroid carcinomas (OTCs), 28 additional PDTCs, and one differentiated high-grade thyroid carcinoma was also screened using two antibody clones, VFF-7 and VFF-18.\n\nIn the exploratory cohort, 10 of 33 tumors (30%) showed focal or diffuse CD44v6 expression, while the rest were negative. Among OTCs in the validation cohort, 15 of 40 (38%) were partially or diffusely positive, and in PDTCs, 14 of 28 (50%) showed focal or diffuse staining. The VFF-7 and VFF-18 clones produced similar patterns.\n\nSubstantial subsets of non-ATCs express CD44v6, indicating that some patients may be candidates for [1\u2077\u2077Lu]Lu-DOTA-AKIR001 radiotherapy, particularly when conventional treatments are exhausted.", "doi": "10.1186/s13044-025-00266-3", "pmid": "41039489", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12492884"}, {"db": "pii", "key": "10.1186/s13044-025-00266-3"}], "notes": [], "created": "2026-08-20T12:21:23.208Z", "modified": "2026-08-20T12:21:23.293Z"}], "created": "2026-08-20T12:21:23.254Z", "modified": "2026-08-20T12:21:23.254Z"}